Recombinant human activated protein C, drotrecogin alfa (activated): A novel therapy for severe sepsis

Pharmacotherapy

Volumn 21, Issue 11, 2001, Pages 1389-1402

  Kanji, Salmaan ^a,c   Devlin, John W ^a,c   Piekos, Krista A ^b,c   Racine, Eric ^b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; UNCLASSIFIED DRUG;

BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DEATH; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HUMAN; MORTALITY; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SHORT SURVEY; TREATMENT INDICATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 0035162616     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.17.1389.34417     Document Type: Article

References (67)

1. American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients
2. Sepsis: A new hypothesis for pathogenesis of the disease process
3. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study
4. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care
5. Age-specific incidence and outcome of sepsis in the U.S.
6. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987
7. Epidemiology of sepsis syndrome in 8 academic medical centers: Academic medical center consortium sepsis project working group
8. Coagulation inhibitors in sepsis and disseminated intravascular coagulation
9. Immunological therapy in sepsis: Currently available
10. Immunological therapy of sepsis: Experimental therapies
11. Coagulation inhibitor replacement in sepsis is a potentially useful clinical approach
12. New concepts in activation of the clotting cascade in sepsis
13. Efficacy and safety of recombinant human activated protein C for severe sepsis
14. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
15. Molecular biology of septic shock
16. Molecular basis of hostpathogen interaction in septic shock
17. Definition of sepsis
18. Treating patients with severe sepsis
19. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
20. 2 formation is increased in human sepsis syndrome: Effects of cyclooxygenase inhibition
21. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia
22. Inflammation, sepsis and coagulation
23. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock
24. Activation of coagulation after administration of tumor necrosis factor to normal subjects
25. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
26. The protein C pathway
27. Cell mediated events that control blood coagulation and vascular injury
28. Inflammation and thrombosis: Mutual regulation by protein C
29. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects
30. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes
31. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, INF, or phorbol ester
32. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation
33. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies
34. Time course of hemostatic abnormalities in sepsis and its relation to outcome
35. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict high mortality
36. Changes of the hemostatic network in critically ill patients: Is there a difference between sepsis, trauma, and neurosurgery patients?
37. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
38. Protein C activity at baseline predicts development of shock and 28-day mortality in patients with severe sepsis
39. Protein C (PC) levels in sepsis: Association with mortality
40. Protein C, protein S and C4b-binding protein in severe infection and septic shock
41. Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases
42. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
43. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
44. A model for thrombin protection against endotoxin
45. C4b-binding protein exacerbates the host response to Escherichia coli
46. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis
47. Baseline characteristics of patients enrolled in the phase III trial of rhAPC in severe sepsis
48. Attenuation of sepsis-induced coagulation and inflammation by recombinant human activated protein C
49. Changes in markers of coagulation and inflammation in patients with severe sepsis treated with recombinant human activated protein C
50. Effect of patient baseline characteristics on the mortality reduction associated with recombinant human activated protein C (rhAPC) in patients with severe sepsis
51. Effect of age on mortality reduction associated with recombinant human activated protein C in patients with severe sepsis
52. Effect of baseline protein C, antithrombin and IL-6 levels on the mortality reduction associated with recombinant human activated protein C in patients with severe sepsis
53. A consumer's guide to subgroup analysis
54. The effect of recombinant human activated protein C (rhAPC) on organ dysfunction and functional recovery in severe sepsis
55. The effects of ibuprofen on the physiology and survival of patients with sepsis
56. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock: NORASEPT II study group
57. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acut́e myocardial infarction: ISIS-2
58. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation: Canadian critical care trials group
59. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
60. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
61. Severe sepsis: A new treatment with both anticoagulant and antiinflammatory properties
62. Protein C levels as a prognostic indicator of outcome in sepsis and related disorders
63. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction)
64. Evaluating drugs after their approval for clinical use
65. The effect of recombinant human activated protein C on hospital costs and resource use in severe sepsis
66. Best practices in the development of clinical practice guidelines
67. Low-dose dopamine in acute oliguric renal failure